← All trials
NCT06732973
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2024
- Primary completion
- Jun 6, 2025
- Completion date
- Dec 30, 2025
- First posted
- Dec 13, 2024
- Last posted
- Dec 13, 2024
- Enrollment
- 272
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Junshi Bioscience Co.,Ltd.Lead sponsor
- Sponsor GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.